2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION

2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION
Recruiting
99 years or below
All
70 participants needed

Brief description of study

This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced ultrasound (CEUS) exam the morning prior to embolization, approximately one week post-embolization, and at their one month MRI follow up. The goal is to determine if CEUS can detect residual viable tumor after TACE with greater reliability than MRI.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ['Hepatocellular Carcinoma', 'Chemoembolization, Therapeutic']
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 828782

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.